ZetaMAST (Zeta-MBC-005)
Metastatic Breast Cancer
Phase 2Active
Key Facts
About Zetagen Therapeutics
Zetagen Therapeutics is a clinical-stage biotech focused on transforming the treatment of bone metastases and primary cancers through its proprietary Zeta Platform. The company's lead programs, ZetaMet and ZetaMAST, are in Phase 2a development for breast cancer bone metastases, with promising data showing complete responses and significant pain reduction. Backed by FDA Breakthrough Designations and a recent oversubscribed $12.9M Series B1 financing, Zetagen is advancing a novel treatment paradigm that combines anti-cancer, analgesic, and bone-regenerative effects in a single localized therapy.
View full company profileTherapeutic Areas
Other Metastatic Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Platin-DRP® | Chosa Oncology | Validation |
| Vectorized-VX-765 | Atlanthera | Research |
| AURORA 2 Project Collaboration | Seqalis | Phase 2 |
| BPI-1178 (Eciruciclib) | Beta Pharma | Phase 3 |
| Herzuma® | Celltrion | Marketed |
| Eftilagimod alfa (efti) | Immutep | Phase IIb |
| (Z)-endoxifen | Atossa Therapeutics | Phase 1/2 |
| Bria-IMT™ + CPI | BriaCell Therapeutics | Phase 3 |
| Bria-OTS™ (Bria-BRES™) | BriaCell Therapeutics | Phase 1/2 |